
    
      Outline: After successful vaccine manufacturing, patients receive neoantigen tumor vaccine
      hypodermically (5 injections for each 3 days and then 1 injection for each 3 months till
      recurrence or up to 2 years). Treatment continues in the absence of disease recurrence and
      metastasis or unacceptable toxicity.

      Patients are followed for 2 years or up to the absence of disease recurrence and metastasis.

      Projected accrual: A total of 30 patients will be accrued for this study.
    
  